BASKING RIDGE, NJ, July 25, 2006—William H. (Bill) Crown, MA, PhD, president of i3 Innovus, has been named to this year’s PharmaVOICE 100—a peer-nominated listing of the most inspirational leaders in the pharmaceutical industry. Bill introduced econometric methods, drawn from labor economics, to the pharmaceutical outcomes research literature, providing a new and innovative way to evaluate the effects of drug treatment with real-world data.
Retrospective database studies enable large cohorts of patients to be followed longitudinally to observe their health care utilization and adverse events in real-world treatment settings, as opposed to the carefully controlled settings of clinical trials. The marriage of primary data collection and econometric methods with the database maintained by i3’s parent company, Ingenix, enabled the broadening of data collection beyond de-identified claims to include patient-reported outcomes, such as: Why did the patient change medications? How did the patient function on different drugs? Why was the patient prescribed that particular drug? What impact did that drug have on the patient’s quality of life?
“The impact of Bill’s research on the industry cannot be overstated. His studies are the future in pharmaceutical marketing and research,” said Glenn Bilawsky, CEO of i3 and a member of last year’s Pharma Voice 100. “Bill’s focus on econometrics methodologies to evaluate the cost effectiveness of different treatments was visionary.”
“PharmaVOICE asked its diverse readership to nominate the individuals who have inspired and motivated them,” said Taren Grom, editor-in-chief of Pharma Voice. “Readers were asked to select individuals who view industry trends as challenges not burdens, as opportunities not obstacles, who embody panache and conviction, and who plan for the future rather than respond to change. These innovative creators of outside-the-box and breakthrough strategies, products, and services are pioneering new paths and lifting their companies to greater heights.”
About i3
i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It is composed of i3 Innovus (formerly i3 Magnifi), delivering the science and solutions to achieve marketplace success, i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, engaged in pharmacovigilence and epidemiology; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; and, i3DLN, providing continuing medical education. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit www.i3global.com.
